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tics (relative hazard  1.68; 95% confidence interval: 0.98 toRace-specific association of lipoprotein(a) with vascular access
2.86). No association was found with apo(a) isoform size ininterventions in hemodialysis patients: The CHOICE Study.
either race.Background. Elevated serum levels of lipoprotein(a) [Lp(a)]
Conclusions. Elevated Lp(a) may be a risk factor for arterio-and low molecular weight apolipoprotein(a) [apo(a)] isoforms
venous access complications among black hemodialysis pa-are associated with atherothrombotic disease in the general
tients. Future studies should explore this possibility and bepopulation and in patients with kidney failure. Lp(a) may be
adequately powered to allow race-specific analyses.more atherothrombotic in whites than in blacks. Data on the
relation of Lp(a) and apo(a) isoform size to hemodialysis vascu-
lar access complications are limited.
Methods. We analyzed the intervention-free survival of the Frequent complications related to vascular access are
first arteriovenous (AV) access among 215 white and 112 black a substantial burden in the chronic hemodialysis popula-
incident hemodialysis patients participating in the CHOICE tion, in terms of both patient morbidity and economic
Study, a national multicenter prospective cohort study.
cost. Vascular access-related morbidity is the leading causeResults. Median levels of Lp(a) protein were higher among
of hospitalization among patients receiving chronic hemo-blacks than whites (81.0 versus 37.5 nmol/L; P  0.001) and
dialysis and is associated with an estimated cost of nearlyinversely correlated with apo(a) isoform size (r  0.57; P 
0.001). The incidence rate of access interventions was much $1 billion annually in the United States [1, 2]. Complica-
higher in synthetic grafts (N  193) than native fistulae (N  tions of permanent vascular accesses [that is, native arte-
134; 1.0 vs. 0.5 interventions per access-year; P  0.001) and riovenous (AV) fistulae and synthetic AV grafts] are
in patients with kidney failure primarily due to diabetes melli- most often attributed to thrombosis, usually precipitatedtus (N  161) than others (N  166; 0.9 vs. 0.6; P  0.01), but
by neointimal hyperplasia and resultant stenosis of thedid not differ by race. Blacks in the highest race-specific Lp(a)
venous outflow tract [3]. Data on the mechanisms andquartile (145 nmol/L) had a significantly higher incidence
risk factors for vascular access stenosis and thrombosisrate than other blacks (1.4 vs. 0.7; P  0.04), whereas no
association was found in whites. The association in blacks re- are urgently needed to guide the impending clinical trials
mained after adjustment for access type and other characteris- of agents to prevent vascular access complications.
Lipoprotein(a) [Lp(a)] consists of a low-density lipo-
protein (LDL) particle linked to the glycoprotein apo-
1 Choices for Healthy Outcomes in Caring for ESRD (CHOICE) is a lipoprotein(a) [apo(a)], the size of which is geneticallyPatient Outcomes Research Team studying dialysis care for ESRD. The
determined [4]. Smaller apo(a) phenotypes are associ-CHOICE investigators include Neil R. Powe, John H. Sadler, Michael
J. Klag, Gerard F. Anderson, Eric B. Bass, William Briggs, Ronald Brook- ated with higher Lp(a) levels [5]. In studies of the general
meyer, Josef Coresh, Nancy E. Fink, Klemens Meyer, Andrew Levey, population [6] and in patients with kidney failure [7],
Nathan Levin, Haya R. Rubin, Paul K. Whelton, and Albert W. Wu.
higher levels of Lp(a) have been associated with ather-
Key words: vascular access, lipoprotein(a), hemodialysis, thrombosis, othrombotic disease. The metabolic abnormalities asso-
AV access, atherothrombotic disease. ciated with kidney failure frequently result in elevated
levels of lipoprotein(a) [Lp(a)] as compared to the gen-Received for publication July 2, 2001
eral population [8]. Lp(a) levels are significantly higherand in revised form September 26, 2001
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disease [12] suggest that Lp(a) is less atherothrombotic Baseline data collection
in blacks. Previous studies investigating the relation of Demographic characteristics, primary cause of kidney
Lp(a) levels and vascular access complications have had failure, and date of first chronic dialysis were ascertained
mixed results, but have been limited by inadequate sam- from the Health Care Financing Administration Medical
ple sizes and a failure to apply race specific cutoffs. One Evidence Form (Form 2728), which was completed at
prospective study found a higher risk of access thrombo- initiation of chronic dialysis. Race was categorized as
sis or stenosis among white or Hispanic patients in the black or white (including Hispanic and Asian). Comor-
highest Lp(a) tertile as compared to their counterparts bidity assessment was performed at enrollment using
with lower Lp(a) levels, but no association in blacks [12].
the Index of Coexistent Disease (ICED), a composite
Other studies have found no association in white patients
scoring system based on 19 medical and 11 physical im-[13–15]. Low molecular weight (LMW) apo(a) pheno-
pairment categories [20, 21]. The scores are compiledtypes also have been associated with atherothrombotic
into a summary score representing mild (0 or 1), moder-disease in some studies of the general population [16]
ate (2), or severe comorbidity (3). Specific comorbidand in hemodialysis patients [17, 18].
conditions also were recorded. A patient was categorizedIt is unclear whether Lp(a) and apo(a) size are associ-
as having a positive history of cardiovascular disease ifated with vascular access complications among patients
any of the following were noted in the medical record:on chronic hemodialysis. Data on black patients are espe-
coronary artery disease, myocardial infarction, cerebro-cially limited. Therefore, we conducted a prospective study
vascular disease, or transient ischemic attack.to evaluate the relation of Lp(a) and apo(a) size with
hemodialysis vascular access complications among a cohort
Laboratory methodsof white and black patients initiating chronic hemodialysis.
Blood was drawn prior to the dialysis session a median
of 131 days (interquartile range 110 to 149 days) after
METHODS
starting chronic hemodialysis, centrifuged for 15 minutes
Study design and population at 2500 to 3000 RPM, separated, and refrigerated. Speci-
The study subjects were a subpopulation of patients mens were mailed by overnight carrier, divided into ali-
participating in the Choices for Healthy Outcomes in quots, and stored at 86C until thawed for analysis.
Caring for End-Stage Renal Disease (CHOICE) Cohort Lp(a) levels in plasma were determined by a double mono-
Study [19]. CHOICE is a national, prospective cohort clonal antibody-based enzyme immunoassay (ELISA)
study of incident hemodialysis and peritoneal dialysis that has been demonstrated to be insensitive to the size
patients initiated in 1995 to investigate treatment choices heterogeneity of apo(a) [22]. The Lp(a) particles were
of modality and dose and outcomes of dialysis care. From captured on microtiter plates with a monoclonal anti-
October 1995 to June 1998, 1041 (764 hemodialysis and body (a-6) specific for an epitope on kringle 4 type 2. The
277 peritoneal dialysis) patients were enrolled from 80 captured Lp(a) was then determined with a peroxidase-
dialysis clinics associated with Dialysis Clinic, Incorpo- conjugated monoclonal antibody (a-40) specific for an
rated (DCI, Nashville, TN, USA), New Haven CAPD epitope on kringle 4 type 9, which is present as a single
(New Haven, CT, USA), and the Hospital of St. Raphael copy per molecule. The Lp(a) concentrations were ex-
(New Haven, CT, USA). All study participants were pressed in nmol/L of Lp(a) protein. Because of the high
incident kidney failure patients starting outpatient dial-
degree of size heterogeneity of apo(a), it is not possible to
ysis, were over 17 years of age, and spoke English or
accurately convert Lp(a) values from nmol/L to mg/dL.Spanish. Patients were enrolled a median of 45 days from
However, as a point of reference, the median Lp(a) pro-initiation of chronic dialysis (98% within 4 months). The
tein level of 55.0 nmol/L found in our patient cohort,present study consisted of participants in CHOICE who
approximately corresponds to 22.9 mg/dL of total Lp(a)contributed samples to a specimen bank, used hemodial-
mass. Expressed apo(a) isoforms were separated withysis as their initial renal replacement modality, and first
high-resolution sodium dodecyl sulfate (SDS)-agaroseused an AV access for dialysis within 6 months before
gel electrophoresis and detected by immunoblotting asor after specimen collection (N  412). Participants
previously reported [23]. A standardized nomenclaturewhose first AV access failed prior to the time of specimen
proposed by Marcovina, Hobbs and Albers [24], whichcollection (N  46) or who had incomplete information
relies on a consistent relationship between the numberon vascular access outcomes (N  39) were excluded.
of apo(a) kringle 4 domains and the relative migrationTherefore, this study was conducted on a total of 327
of the isoforms in agarose gel was used to define thepatients followed prospectively for vascular access com-
isoforms. Of the two isoforms expressed in heterozygousplications. The study protocol was approved by the Johns
patients, the one that was predominantly expressed wasHopkins University School of Medicine Institutional Re-
view Board. used in statistical analyses.
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Table 1. Characteristics and biochemical measures of 327 incident hemodialysis patients enrolled in the CHOICE Cohort Study, by race
Overall Whites Blacks P value
N 327 215 112
Native fistula, N (%) 134 (41.0) 98 (45.6) 36 (32.1) 0.02
Age, mean (s.d.) 59.4 (14.1) 60.6 (13.8) 57.2 (14.3) 0.04
Female, N (%) 158 (48.3) 94 (43.7) 64 (57.1) 0.02
Primary cause of kidney failure, N (%)
Diabetes mellitus 161 (49.2) 101 (47.0) 60 (53.6) 0.03
Hypertension 60 (18.4) 33 (15.4) 27 (24.1)
Glomerulonephritis 46 (14.1) 35 (16.3) 11 (9.8)
Other 60 (18.4) 46 (21.4) 14 (12.5)
Index of coexisting disease, N (%)
Mild 116 (35.5) 71 (33.0) 45 (40.2) 0.32
Moderate 130 (39.8) 86 (40.0) 44 (39.3)
Severe 81 (24.8) 58 (27.0) 23 (20.5)
History of peripheral vascular disease, N (%) 85 (26.0) 58 (27.0) 27 (24.1) 0.57
History of cardiovascular disease, N (%) 160 (48.9) 116 (54.0) 44 (39.3) 0.01
Any previous intervention of current vascular access, N (%) 48 (14.7) 31 (14.4) 17 (15.2) 0.85
Lipoprotein(a) (nmol/L), median (IQR) 55.0 (16.9–114.4) 37.5 (10.6–99.4) 81.0 (45.0–137.6) 0.001
Low molecular weight apo(a) isoform, N (%) 131 (40.1) 83 (38.6) 48 (42.9) 0.46
IQR is interquartile range. P value denotes black versus white.
Ascertainment of vascular access information adequately to allow continued use (N  1). To assess
the effect of Lp(a) levels on vascular access thrombosis,Discharge summaries, dialysis flow sheets, and dialysis
additional analyses considering only those interventionsclinic progress notes were collected by clinic coordinators
performed to treat thrombosis, or with no recorded indi-at enrollment, annually, and at the time of withdrawal
cation but consisting of thrombolysis or thrombectomy,from the study due to death, renal transplantation, trans-
were performed.. Incidence rates of first vascular accessfer to a non-participating clinic, or patient refusal to
interventions were calculated and compared acrosscontinue. Vascular access information was abstracted
quartiles by log-linear tests for trends [26]. Cox propor-from these records by two investigators (BCA and JAE).
tional hazards models were used to examine the indepen-The date of the first use of an AV access and its type
dent effects of patient characteristics and biochemicaland location were recorded. The date, cause, and type of
measures on intervention-free access survival [27]. Be-procedure performed for each subsequent access-related
cause previous access interventions may have been re-intervention also were recorded.
lated to the other risk factors under study, this character-
Statistical analysis istic was not included in the multivariate models. To
account for possible correlation of outcomes within he-Univariate comparisons of continuous variables across
modialysis clinics, robust estimates of variance were usedsubgroups were made using the non-parametric Mann-
for all multivariate analyses [28]. Statistical analyses wereWhitney U test for medians and Student t test for means
performed using Stata statistical software [29].of variables with normal distributions. Dichotomous
variables were compared using the chi-squared test.
Lp(a) levels were divided into quartiles. Due to the dif- RESULTS
ference in the distribution of Lp(a) levels in blacks as
Study populationcompared to whites, there were few blacks in the lowest
Patient characteristics and biochemical measures ofLp(a) quartile. Therefore, race-specific Lp(a) quartiles
the 327 patients included in this study are shown in Tablealso were constructed. Kaplan-Meier curves for interven-
1. These patients were enrolled at 67 clinics in 17 states.tion-free access survival from the first use of an AV
The 327 patients included in this study were more likelyaccess after blood was drawn for analysis until the first
than the remaining 437 CHOICE patients who receivedaccess-related intervention not due to infection or failure
hemodialysis as their initial renal replacement modalityof an access to mature adequately to allow continued
enrolled in CHOICE to have mild comorbidity (35.5use were constructed for the entire study population and
vs. 26.3%; P  0.006) and less likely to have severeafter stratification by patient characteristics and Lp(a)
comorbidity (24.8 vs. 35.3%; P 0.002), but these groupsquartiles [25]. Patients were censored at the time of death
were similar in terms of age, sex, race, presence of diabe-(N  32), renal transplantation (N  20), transfer to
tes mellitus, history of peripheral and cardiovascular dis-a non-participating clinic (N  11), patient refusal to
ease, and Lp(a) levels. The 39 patients excluded due tocontinue (N  12), or any intervention recorded as due
to infection (N  5), or failure of an access to mature incomplete follow-up did not differ significantly from the
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Table 2. Incidence rate per access-year of vascular access interventions among 327 incident hemodialysis patients enrolled in the CHOICE
Cohort Study, by race and patient characteristics
Overall (N  327) Whites (N  215) Blacks (N  112)
Incidence Incidence Incidence
rate P value rate P value rate P value
Overall 0.74 0.67 0.89 0.10
Access type
Native fistula 0.49 0.001 0.40 0.001 0.75 0.39
Synthetic graft 0.95 0.95 0.96
Sex
Male 0.69 0.54 0.55 0.03 1.18 0.04
Female 0.79 0.86 0.71
Age group
50 0.61 0.14a 0.56 0.25a 0.69 0.20a
50–60 0.80 0.67 1.04
60–70 0.72 0.67 0.82
70 0.90 0.80 1.33
Primary cause of kidney failure
Diabetes mellitus 0.90 — 0.91 — 0.86 —
Hypertension 0.64 0.14b 0.45 0.03b 0.98 0.75b
Glomerulonephritis 0.52 0.04b 0.44 0.02b 0.76 0.70b
Other 0.62 0.11b 0.52 0.05b 0.94 0.90b
Index of coexistent disease
Mild 0.61 0.02a 0.38 0.001a 1.09 0.26a
Moderate 0.74 0.73 0.74
Severe 1.00 1.10 0.80
History of peripheral vascular disease
Negative 0.70 0.19 0.62 0.18 0.86 0.64
Positive 0.87 0.82 0.98
History of cardiovascular disease
Negative 0.67 0.16 0.52 0.02 0.93 0.66
Positive 0.83 0.84 0.82
Previous interventions of current vascular access
Negative 0.58 0.001 0.51 0.001 0.74 0.01
Positive 1.95 2.07 1.77
a Test for trend
b Versus diabetes mellitus
included study population in any of these characteristics. access intervention (incidence rate 0.74 interventions/
White patients were much more likely to use a native access-year). The indications for intervention were re-
fistula than were black patients, were more likely to have corded as thrombosis (52%), stenosis (18%), or steal
a history of cardiovascular disease, and were less likely syndrome (1%) or were not recorded (33%). The proce-
to be female and have hypertension as the underlying dures performed were recorded as angioplasty (29%),
cause of kidney failure. The mean age of white patients thrombolysis (22%), surgical revision (17%), thrombec-
was 3.4 years higher than that of black patients. tomy (11%), or access removal (5%) or were not re-
The median Lp(a) level in the whole cohort was 55.0 corded (29%). The incidence rate of access-related inter-
nmol/L (interquartile range 16.9 to 114.4 nmol/L). How- ventions was much higher among those patients who
ever, as previously reported [30], Lp(a) levels were sig- used a synthetic AV graft than those who used an AV
nificantly higher in blacks than in whites (median 81.0 fistula (0.95 vs. 0.49 interventions/access-year; P 0.001),
vs. 37.5 nmol/L; P  0.001). Lp(a) levels did not differ among patients with kidney failure primarily caused by
by patient age, sex, type of vascular access, comorbid diabetes mellitus than others (0.90 vs. 0.60 interventions/
disease status, or history of peripheral or cardiovascular
access-year; P  0.01), and among those with severe asdisease. There was no significant difference by race or
compared to mild or moderate comorbid disease (1.00sex in the time from the first hemodialysis session or the
vs. 0.68 interventions/access-year; P  0.03; Table 2).first use of a permanent vascular access to the time of
In analyses stratified by race, these associations wereblood collection for analysis. Lp(a) concentration was
statistically significant only in white patients. Female pa-inversely correlated with apo(a) isoform size (r0.57;
tients had a higher incidence rate among whites, but aP  0.001).
lower incidence rate among blacks. The incidence rate
Vascular access interventions of a subsequent intervention among patients who had
undergone a previous intervention (prior to blood collec-During a median follow-up of 10 months (range 0 to
36 months), 156 of the 327 patients underwent a vascular tion) on the AV access in use was more than three times
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Table 3. Incidence rate per access-year of vascular access interventions (95% confidence interval, CI) among 327 incident hemodialysis
patients enrolled in the CHOICE Cohort Study, by quartiles of biochemical measures and race
Overall (N  327) Whites (N  215) Blacks (N  112)
Incidence rate Incidence rate Incidence rate
Quartile (95% CI) Quartile (95% CI) Quartile (95% CI)
Lipoprotein(a) nmol/L
1 17 0.74 (0.54–1.00) 11 0.74 (0.50–1.07) 45 0.69 (0.42–1.15)
2 17–55 0.69 (0.50–0.94) 11–40 0.73 (0.50–1.07) 45–80 0.91 (0.53–1.57)
3 55–116 0.79 (0.57–1.09) 41–100 0.73 (0.49–1.08) 81–145 0.77 (0.47–1.28)
4 116 0.77 (0.56–1.05) 100 0.51 (0.33–0.80) 145 1.38 (0.86–2.21)a
Apolipoprotein(a) isoform size
(No. of Kringle 4)
1 19 0.78 (0.58–1.04) 0.62 (0.42–0.91) 1.20 (0.77–1.89)
2 19–22 0.58 (0.40–0.83) 0.59 (0.37–0.95) 0.56 (0.32–0.99)
3 23–27 0.71 (0.52–0.97) 0.69 (0.46–1.03) 0.74 (0.45–1.23)
4 27 0.91 (0.67–1.22) 0.78 (0.54–1.12) 1.36 (0.81–2.30)
a P  0.05 versus lowest quartile
higher than the incidence rate among patients that had mary cause of kidney failure, comorbid disease status
and history of peripheral vascular disease. A term for thenot undergone a previous intervention.
There was no association between the overall Lp(a) interaction of race and Lp(a) quartile was not statistically
significant (P  0.30). There was no significant associa-quartiles and incidence of vascular access interventions
in the total population, or in whites or blacks separately tion between the highest Lp(a) quartile, as compared to
the lowest, with the time to the first access intervention(Table 3). There was a trend toward higher incidence
rates with higher race-specific Lp(a) quartiles among among the total study population (relative hazard 0.97;
blacks, but this did not reach statistical significance P 0.89), or in whites (relative hazard 0.86; P 0.56)
(P-trend  0.10). Black patients in the highest race- or blacks (relative hazard  1.13; P  0.84) separately,
specific Lp(a) quartile had a significantly higher inci- after adjustment. The highest race-specific Lp(a) quartile
dence rate than did their counterparts in the lowest among blacks, however, was associated with a relative
quartile (1.38 vs. 0.69 interventions/access-year; P  hazard of 1.68 (95% confidence interval 0.98 to 2.86; P 
0.05) or those in the lower three quartiles combined (1.38 0.06), as compared to the lower three quartiles, after
vs. 0.78 interventions/access-year; P  0.04). Whites in adjustment. The association of Lp(a) quartile and access
the highest race-specific Lp(a) quartile had a lower inci- interventions among blacks did not change (relative haz-
dence rate than other whites, but this difference was not ard associated with the highest Lp(a) quartile 1.68; P
statistically significant (0.51 vs. 0.73 interventions/access- 0.07) in analyses that included only those interventions
year; P  0.17). Apo(a) isoform size quartile was not performed to treat thrombosis or with no recorded indi-
associated with the incidence of vascular access interven- cation but consisting of thrombolysis or thrombectomy
tions in blacks, whites, or overall. (incidence rate 0.37 interventions/access-year). Similar
results were obtained after stratification by access type
Multivariate analyses (relative hazard associated with the highest Lp(a) quar-
In a multivariate Cox proportional hazards model of tile in black patients with native fistulae  1.78; with
the total population, synthetic grafts were associated grafts 1.81) or sex (relative hazard 1.43 in men; 1.62
with a 78% higher risk of an access intervention than in women), and in analyses excluding accesses having
were native fistulae (P  0.01; Table 4). Among white undergone previous interventions (relative hazard 
patients, kidney failure due to diabetes (P  0.02) and 1.43). Apo(a) isoform size was not associated with the
moderate (P  0.03) or severe (P  0.01) comorbid incidence of vascular access interventions in blacks,
disease status also were associated with a higher risk of whites, or overall in adjusted analyses.
an access intervention. Among black patients, male sex
was associated with a 78% higher risk (P  0.03).
DISCUSSIONLp(a) concentration, categorized by overall quartile
In this study of a cohort of patients starting chronicwas not significantly associated with the time to the first
hemodialysis, a continuous association of Lp(a) concen-vascular access intervention among the total study popu-
tration with vascular access interventions was not evi-lation (relative hazard per quartile  0.99; P  0.90), or
dent, but the highest race-specific quartile of Lp(a) levelsamong whites (relative hazard per quartile  0.94; P 
was associated with a higher risk of interventions for0.49) or blacks (relative hazard per quartile  1.16; P 
0.40) separately, after adjusting for access type, sex, pri- permanent vascular access-related complications among
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Table 4. Adjusted relative hazard (95% confidence interval) of a vascular access intervention associated with patient characteristics and
biochemical measures among 327 incident hemodialysis patients enrolled in the CHOICE Cohort Study, by race
Overall (N  327) Whites (N  215) Blacks (N  112)
Adjusted Adjusted Adjusted
relative hazard (95% CI) relative hazard (95% CI) relative hazard (95% CI)
Synthetic graft (vs. native fistula) 1.78 (1.12–2.80)a 1.95 (1.00–3.82)a 1.67 (0.81–3.44)
Male vs. female 1.10 (0.75–1.61) 0.80 (0.49–1.30) 1.78 (1.05–3.02)a
Primary cause of kidney failure
Other 1.00 Referent 1.00 Referent 1.00 Referent
Diabetes mellitus 1.30 (0.96–1.77) 1.61 (1.08–2.40)b 0.80 (0.51–1.26)
Index of coexistent disease
Mild 1.00 Referent 1.00 Referent 1.00 Referent
Moderate 1.07 (0.72–1.60) 1.72 (1.05–2.81)a 0.61 (0.30–1.26)
Severe 1.31 (0.78–2.19) 2.13 (1.20–3.80)b 0.78 (0.30–2.03)
Black versus white 1.15 (0.71–1.87) — — — —
History of peripheral vascular disease 1.12 (0.77–1.64) 1.09 (0.69–1.72) 1.10 (0.57–2.09)
Race-specific lipoprotein(a) quartile
1 1.00 Referent 1.00 Referent 1.00 Referent
2 0.94 (0.61–1.45) 0.99 (0.50–1.94) 1.38 (0.55–3.47)
3 0.95 (0.63–1.42) 0.96 (0.56–1.64) 1.29 (0.57–2.93)
4 0.97 (0.63–1.50) 0.72 (0.44–1.18) 2.02 (0.88–4.62)
Low molecular weight apo(a) isoform 0.85 (0.59–1.23) 0.83 (0.51–1.34) 1.08 (0.64–1.83)
a P  0.05, b P  0.01
black but not white participants. Apo(a) isoform size was larger than in previous studies. Because of the wide inter-
individual range and skewed distribution, a large samplenot significantly associated with the risk of vascular access
interventions in either race. Synthetic grafts and previous size is required to reliably detect differences in Lp(a)
levels between groups [32]. The difference in the distri-access interventions were associated with a higher risk
in both blacks and whites. The results of previous studies bution of Lp(a) levels in blacks as compared to whites,
and the previous data suggesting that elevated Lp(a)that have investigated the relation of Lp(a) levels and
vascular access complications have been inconsistent. In levels may be more atherothrombotic in whites than in
blacks, suggest that these populations should be analyzedthe largest previous study, Goldwasser et al followed 59
white or Hispanic and 65 black hemodialysis patients for separately [9]. The large size and racial diversity of the
cohort studied provide adequate power to detect mean-up to 14 months [12]. They found that the 11 white or
Hispanic patients with Lp(a) levels in the upper tertile ingful effects in separate analyses of black and white
patients. Importantly, previous studies that have foundof the population (57 mg/dL) were at a higher risk of
vascular access thrombosis or stenosis than their counter- no association between Lp(a) levels and vascular access
complications in blacks have compared patients withparts with lower Lp(a) levels (adjusted relative risk 
2.9; P  0.05). The 29 black patients in the upper Lp(a) Lp(a) levels above versus below an arbitrary cut-off de-
fined by the distribution of Lp(a) levels in the total popu-tertile, however, were at no higher risk compared to their
counterparts with lower Lp(a) levels (adjusted relative lation. As Lp(a) levels are much higher in blacks than
in whites, Lp(a) levels in blacks above this cut-off mayrisk  0.9; P  0.91). A study of 40 white patients simi-
larly found that patients in the highest Lp(a) quartile not represent elevated levels with respect to the distribu-
tion among all black patients. The larger population and(52.5 mg/dL) had significantly lower intervention-free
vascular access survival at one year than the patients in racial distribution of the current study also allow analysis
of race-specific Lp(a) quartiles.the lower three quartiles (40 vs. 72%; P  0.05) [31]. In
contrast, no association was observed between Lp(a) Second, the population in the present study is repre-
sentative of hemodialysis patients in the United States.levels and venous outflow stenoses among 30 non-dia-
betic patients with native AV fistulae followed for up to The characteristics of patients in this study are similar
to those in national samples (for example, Waves 1 andtwo years [13], or between Lp(a) levels and a history of
graft or fistula occlusion among 47 white patients [14]. 2 of the Dialysis Morbidity and Mortality Study) [33, 34].
Previous studies each represent a single center’s experi-Sirrs et al found no significant association between Lp(a)
levels and access interventions in a prospective study of ence, whereas the patients in the current study were
enrolled at 67 different dialysis clinics. Also, the present88 patients, over 90% of whom were white or Asian,
followed for nine months [15]. study included both native AV fistulae and synthetic
AV grafts, whereas several of the previous studies wereThe current study differs from these previous reports
in several important ways. First, the population is much limited to AV fistulae [13, 15, 31]. We found a similarly
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increased risk associated with Lp(a) levels in the highest study may be due to early access dysfunction or recent
surgical placement of a permanent access, rather thanquartile among black patients with either native fistulae
(relative hazard 1.78) or synthetic grafts (relative haz- being a cause of access complications. There was no
difference by race, however, in the time from the firstard  1.81). The distribution of vascular access types in
use at 30 and 60 days after initiation of chronic hemodial- use of a permanent vascular access to the time of blood
collection, so it is unlikely that an acute phase reactionysis in this study are also similar to data reported from
the USRDS [33–35]. explains the differential association by race. It is possible
that the risks of neointimal hyperplasia or thrombosis,Thirdly, this is the first study of the association of
Lp(a) with vascular access events to measure Lp(a) con- the most frequent causes of vascular access dysfunction,
are increased only at extremely high levels of Lp(a).centration rather than total Lp(a) mass, which is sensitive
to the size heterogeneity of apo(a). Analysis of Lp(a) These levels are only seen in the highest Lp(a) quartile
of blacks in our study. There may be too few whites withconcentration should provide a more accurate represen-
tation of any biological effect of Lp(a) molecules on such extremely elevated levels to detect any increased
risk among these patients. The Lp(a) level at which thevascular access complications. We found no association
of vascular access interventions with apo(a) isoform size, risk of atherogenesis, and therefore cardiovascular com-
plications, is increased may be lower, allowing detectionsuggesting that this characteristic does not directly influ-
ence the thrombogenicity of Lp(a). of an increased risk among white patients. Recently iden-
tified genetic polymorphisms that may control the ath-Another important difference is that the patients in-
cluded in the present study were incident hemodialysis erogenicity of Lp(a) may play a role in the racial differ-
ences observed [40, 41]. The wide range and highlypatients, as opposed to prevalent patients, and the ac-
cesses studied were the first AV accesses used by these skewed distribution of Lp(a), especially among white
patients, make studies of Lp(a) prone to random devia-patients. This difference may be important, as previous
studies are subject to a larger vascular access survival tions [32], and the possibility that these results are due
to random variation cannot be ruled out.bias wherein many patients with a failed access may have
required dialysis catheters for subsequent access, and In agreement with numerous previous studies, syn-
thetic grafts were much more likely to require an inter-would therefore have been excluded. If Lp(a) or apo(a)
isoform size are associated with mortality, another survi- vention than were native fistulae in our population [42].
Despite the consistency of results demonstrating that fis-vor bias would exclude patients dying from Lp(a)-related
mortality from being enrolled. Alternatively, the effects tulae have superior long-term performance, the propor-
tion of patients starting chronic hemodialysis in the U.S.of Lp(a) on vascular access complications may be differ-
ent for new as opposed to established accesses, or in who receive a fistula has declined in the last decade [43].
Increasing the proportion of hemodialysis patients usingpatients initiating hemodialysis as compared to prevalent
kidney failure patients with a longer duration of hemodi- a native fistula may be an important step in decreasing
the incidence of vascular access-related morbidity in thealysis.
A role for Lp(a) in vascular access complications is U.S. hemodialysis population. This study also confirms
earlier reports that patients with kidney failure primarilysuggested by the homology of apo(a) to plasminogen
[32]. This homology allows Lp(a) to compete with plas- due to diabetes mellitus are at significantly higher risk
of access complications than patients with kidney failureminogen for fibrin binding sites and for plasminogen
receptors on endothelial cells, thereby blocking fibrinol- due to other causes [44]. This association was limited to
white patients in the present study. This race-specificysis and promoting thrombosis [36]. This disruption of
plasminogen activity also inhibits transforming growth association should be explored in future studies.
Among black patients, females had a lower risk offactor- and results in the promotion of smooth muscle
cell proliferation [37]. Further evidence of a role for Lp(a) access interventions, after adjustment, than did their
male counterparts. No such association was observedin atherosclerosis is provided by its presence in athero-
sclerotic lesions of saphenous vein bypass grafts [38]. In in white patients. This association is not in agreement
with previous reports, which have found no associationour study, higher levels of Lp(a) were associated with a
higher risk of vascular access complications among blacks, [42, 45] or an association in the opposite direction [46],
though several of these did not account for access type.but were not associated with a higher risk among whites.
This race-specific association of Lp(a) levels with the This finding, however, is based on results in relatively
few black males (N  48) included in this study.risk of access complications was unexpected given the
previous evidence that Lp(a) may be more atherothrom- This study has several limitations. Although this is the
largest study of the relationship of Lp(a) levels withbotic in whites than in blacks [10–12]. Explanations for
this association are speculative. There is evidence that vascular access complications to date, complete data
were not available for all patients enrolled in CHOICE.Lp(a) is an acute-phase reactant [39], so higher Lp(a)
levels observed at four months after enrollment in this This is not expected to substantially bias the results,
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